Abstracts tagged "Outcome measures"

Abstract Number: 139 • 2020 Pediatric Rheumatology Symposium
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
Mia Glerup¹, Ellen D Arnstad ², Veronika Rypdal ³, Suvi Peltoniemi ⁴, Kristiina Aalto ⁵, Marite Rygg ⁶, Susan Nielsen ⁷, Anders Fasth ⁸, Lillemor Berntson ⁹, Ellen Nordal ³ and Troels Herlin ¹⁰, ¹Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology, and Department of Pediatrics, Levanger Hospital, Nord-Trøndelag Hospital Trust, Levanger, Norway., Tromheim, Norway, ³Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway., Tromsø, Norway, ⁴Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., Helsinki, Finland, ⁵Department of Pediatrics, New Children's Hospital, Helsinki University Hospital, Pediatric Research Center, University of Helsinki, Helsinki, Finland., HUS, Finland, ⁶Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ⁷Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Copenhagen, Denmark, ⁸Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁹Department of Womens and Childrens Health, Uppsala University, Uppsala, Sweden., Uppsala, Sweden, ¹⁰Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark., Aarhus N, Denmark
Background/Purpose: Previously, we showed that ILAR JIA categories defined at disease onset change considerably during the first 8 years of disease course. Whether achieved remission…
Abstract Number: 341 • 2019 ACR/ARP Annual Meeting
Development of a Multivariable Improvement Measure for Gout
Naomi Schlesinger¹, N. Lawrence Edwards ², Anthony Yeo ³ and Peter Lipsky ⁴, ¹Division of Rheumatology, Department of Medicine, Rutgers, The State University of New Jersey, New Brunswick, NJ, ²Department of Medicine, University of Florida, Gainesville, FL, ³Horizon Therapeutics plc, Lake Forest, IL, ⁴AMPEL BioSolutions, LLC, Charlottesville, VA
Background/Purpose: Gout is a multifactorial inflammatory disease in which patients experience a wide range of signs and symptoms, including flares, inflammatory arthritis, tophi and disability.…
Abstract Number: 356 • 2019 ACR/ARP Annual Meeting
Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Till Uhlig¹, Lars Fridtjof Karoliussen ², Espen A Haavardsholm ², Tore Kvien ¹ and Hilde Hammer ², ¹Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ²Diakonhjemmet hospital, Oslo, Norway
Background/Purpose: Urate lowering therapy (ULT) is expected to prevent new gout flares. Treat-to-target ULT is however often not performed, and more evidence on how often…
Abstract Number: 767 • 2019 ACR/ARP Annual Meeting
Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains
Casey A. Rimland¹, Kaitlin Quinn ², Joel S. Rosenblum ³, Mollie Schwartz ⁴, K Bates Gribbons ⁵, Elaine Novakovich ⁶, Antoine Sreih ⁷, Peter Merkel ⁷, Mark A. Ahlman ⁸ and Peter C. Grayson ⁹, ¹National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, ²Georgetown University Hospital/National Institutes of Health, Washington, DC, ³National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, ⁴University of Maryland, Baltimore, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Large-vessel vasculitis (LVV) is characterized by inflammation of the aorta and its major branches. The most common forms of LVV include giant cell arteritis…
Abstract Number: 1655 • 2019 ACR/ARP Annual Meeting
Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
Kimberly Showalter¹, Cynthia Magro ², Dana Orange ³, Yaxia Zhang ⁴, Phaedra Agius ⁵, Jackie Finik ⁶, Robert Spiera ¹ and Jessica Gordon ¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, ³Rockefeller University, New York, ⁴Hospital for Special Surgery, New York, ⁵New York Genome Center, New York City, ⁶Hospital for Special Surgery, New York, NY, New York, NY
Background/Purpose: The association between systemic sclerosis (SSc) skin histology and clinical findings is not fully characterized. In two SSc trials, we developed a scoring system…
Abstract Number: 2473 • 2019 ACR/ARP Annual Meeting
Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Michelle Mulder¹, Alfons den Broeder ¹, Berbke van Ginneken ¹, Elien Mahler ¹, Frank van den Hoogen ¹, Johanna Vriezekolk ¹ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease, with involvement of at least five health domains: peripheral joint disease, enthesitis, dactylitis, axial involvement, and skin…
Abstract Number: 2840 • 2019 ACR/ARP Annual Meeting
Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy
Didem Saygin¹, Chester Oddis ¹, Nicole Neiman ¹, Diane Koontz ¹, Siamak Moghadam-Kia ¹ and Rohit Aggarwal ¹, ¹University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare, debilitating systemic diseases characterized by proximal muscle weakness, which limit activities of daily living and…
Abstract Number: 481 • 2018 ACR/ARHP Annual Meeting
Stepping It up: The Use of Physical Activity Monitors As an Outcome Measure in Juvenile Myositis
Emily Brunner¹, Laura Tasan², Kathryn S. Torok³, Bonny Rockette-Wagner⁴, Christina K. Zigler⁵, Kaila Schollaert-Fitch³, Diane Koontz⁶, Chester V. Oddis⁷ and Rohit Aggarwal⁸, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Physical Medicine & Rehabilitation, University of Pittsburgh, Pittsburgh, PA, ⁶Internal Medicine Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, Department of Medicine, Unviersity of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh/University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: The use of physical activity monitors (PAM), which objectively quantify free-living movement, may enhance assessment of disease activity in juvenile myositis (JM) clinical trials…
Abstract Number: 2687 • 2018 ACR/ARHP Annual Meeting
Patient-Level Evaluation of Components of the American College of Rheumatology Combined Response Index in Systemic Sclerosis (CRISS) Using Patient-Reported Anchors
Vivek Nagaraja¹, John Powers², Celia J. F. Lin³, Benjamin Brennan⁴, Veronica J. Berrocal⁵ and Dinesh Khanna¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²University of Maryland School of Medicine, Rockville, MD, ³Genentech, Inc., South San Francisco, CA, ⁴School of Public Health, University of Michigan, Ann Arbor, MI, ⁵Div of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Treatment benefit is demonstrated by evidence that interventions have positive impacts on how patients feel, function, and/or survive (FDA Guidance, 21CFR314.510). The ACR CRISS,…
Abstract Number: 681 • 2018 ACR/ARHP Annual Meeting
Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor
Dan Gromer¹, Laura C. Coates², Oliver FitzGerald³, Blanca Himes⁴, Philip Helliwell⁵ and Alexis Ogdie⁶, ¹University of Pennsylvania, Medical Student, Philadelphia, PA, ²University of Oxford, Oxford, United Kingdom, ³Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁴Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁵LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that affects the skin, joints, and soft tissues. No metrics exist to indicate whether an…
Abstract Number: 2783 • 2018 ACR/ARHP Annual Meeting
EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases
Lisa Ehlers¹, Johan Askling², Johannes W. J. Bijlsma³, Maria C. Cid⁴, Maurizio Cutolo⁵, Bhaskar Dasgupta⁶, Christian Dejaco^7,8, William G Dixon⁹, Nils Feltelius^10,11, Axel Finckh¹², Kate Gilbert¹³, Sarah Mackie¹⁴, Alfred Mahr¹⁵, Eric L. Matteson¹⁶, Lorna Neill¹⁷, Carlo Salvarani^18,19, Wolfgang A. Schmidt²⁰, Anja Strangfeld²¹, Ronald van Vollenhoven²² and Frank Buttgereit¹, ¹Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, ²Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴University of Barcelona, Barcelona, Spain, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁶Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁷Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ⁸Rheumatology, Hospital of Bruneck, Bruneck, Italy, ⁹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ¹⁰Medical Products Agency, Uppsala, Sweden, ¹¹Cross-Committee Task Force on Registries at the European Medicines Agency, London, United Kingdom, ¹²University Hospital of Geneva, Geneva, Switzerland, ¹³Patient Representative from PMRGCAuk, London, United Kingdom, ¹⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, ¹⁵Internal Medicine, Saint-Louis Hospital, Paris Diderot University, Paris, France, ¹⁶Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁷Patient Representative from PMR-GCA Scotland, Perth, United Kingdom, ¹⁸Università di Modena e Reggio Emilia, Modena, Italy, ¹⁹Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ²⁰Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ²¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis, and is frequently associated with comorbidities related either to the disease…
Abstract Number: 723 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Cognitive Screen Does Not Identify Cognitive Sub-Domains: Exploration of the Subscale Structure of the Perceived Deficits Questionnaire in a Systemic Lupus Erythematosus Cohort
Lisa Engel¹, Jiandong Su¹, Emily Nalder², Yael Goverover³, Monique Gignac⁴, Carmela Tartaglia⁵, Nicole Anderson¹ and Zahi Touma¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Occupational Science and Occupational Therapy, University of Toronto, Toronto, ON, Canada, ³Department of Occupational Therapy, New York University, New York, NY, ⁴Instititue for Work and Health, Toronto, ON, Canada, ⁵University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada
Background/Purpose: Identifying patients with Systemic Lupus Erythematosus related cognitive impairment (SLE-CI) is critical as SLE-CI can negatively affect employment, quality of life, and disease self-management.…
Abstract Number: 2857 • 2018 ACR/ARHP Annual Meeting
An Electronic Audit, Reporting, and Data Correction System Improves the Quantity and Quality of Observational Data Collected for US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
Grant W. Cannon^1,2, Jorge Rogas², Neill Bell³, Joshua Baker⁴, Gail S. Kerr⁵, Angelo Gaffo⁶, J. Steuart Richards⁷, Jennifer Barton⁸, Pascale Schwab⁸, Ted R. Mikuls⁹, Namrata Singh¹⁰, Liron Caplan¹¹, Deana Lazaro¹², Andreas Reimold¹³ and Brian Sauer², ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ³Salt Lake City VA Medical Center and University of Utah, Dallas VA Medical Center, Dallas, TX, ⁴Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ⁵Washington VA Medical Center, Georgetown and Howard Universities, Washington, DC, ⁶Birmingham VA and University of Alabama at Birmingham, Birmingham, AL, ⁷Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA, ⁸VA Portland Health Care System and Oregon Health and Science, Portland, OR, ⁹VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ¹⁰Internal Medicine, Iowa City VA Medical Center and University of Iowa, Iowa City, IA, ¹¹Div of Rheumatology, Denver VA Medical Center and University of Colorado, Aurora, CO, ¹²Brooklyn VA Medical Center and SUNY Downstate, Brooklyn, NY, ¹³Rheumatology, Dallas VA Medical Center and University of Texas - Southwestern, Dallas, TX
Background/Purpose: The Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry is an observational cohort study of US Veterans with RA at 11 VA Medical…
Abstract Number: 1261 • 2018 ACR/ARHP Annual Meeting
Development a Core Domain Set to Assess Shared Decision Making Interventions in Rheumatology: An OMERACT White Paper to Facilitate Endorsement
Karine Toupin-April¹, Jennifer Barton^2,3, Liana Fraenkel⁴, Alexa Meara⁵, Linda Li⁶, Peter Brooks⁷, Maarten de Wit⁸, Dawn Stacey^9,10, France Légaré¹¹, Beverly Shea^9,12,13, Anne Lyddiatt¹⁴, Catherine Hofstetter¹⁵, Robin Christensen¹⁶, Marieke Scholte-Voshaar^17,18, Maria Suarez-Almazor¹⁹, Annelies Boonen²⁰, Tanya Meade^21,22, Lyn March²², Janet Elizabeth Jull⁹, Willemina Campbell²³, Rieke Alten²⁴, Suvi Karuranga²⁵, Esi Morgan²⁶, Jessica Kaufmann²⁷, Sophie Hill²⁷, Lara J. Maxwell^9,10, Dorcas Beaton²⁸, Yasser El-Miedany²⁹, Shikha Mittoo³⁰, Susan J. Bartlett³¹, Jasvinder A. Singh³² and Peter Tugwell³³, ¹Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ²VA Portland Health Care System, Portland, OR, ³Oregon Health & Science University, Portland, OR, ⁴Yale University School of Medicine, New Haven, CT, ⁵Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁶Arthritis Research Canada, Richmond, BC, Canada, ⁷The University of Melbourne, Victoria, Australia, ⁸EULAR standing committee of PARE, Zurich, Switzerland, ⁹University of Ottawa, Ottawa, ON, Canada, ¹⁰The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹¹Université Laval, Montreal, QC, Canada, ¹²Bruyere Research Institute, Ottawa, ON, Canada, ¹³School of Epidemiology, Public Health, and Preventive Medicine, Faculty of Medicine, University of Ottawa, and Ottawa Hospital Research Institute, Clinical Epidemiology Program, Ottawa, ON, Canada, ¹⁴Musculoskeletal Group, Cochrane Collaboration, Hamilton, ON, Canada, ¹⁵OMERACT patient research partner group, Ottawa, ON, Canada, ¹⁶Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ¹⁷University of Twente, Enschede, ON, Netherlands, ¹⁸OMERACT patient research partner group, Enschede, Netherlands, ¹⁹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²⁰Department of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands, Maastricht, Netherlands, ²¹Western Sydney University, New South Wales, Australia, ²²University of Sydney, New South Wales, Australia, ²³OMERACT patient research partner group, Toronto, ON, Canada, ²⁴University Medicine Berlin, Berlin, Germany, ²⁵Access to Medicine Foundation, Haarlem, Netherlands, ²⁶University of Cincinnati, Cincinnati, OH, ²⁷La Trobe University, Victoria, Australia, ²⁸Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada, ²⁹Ain Shams University, Cairo, Egypt, ³⁰Involved medicine, Toronto, ON, Canada, ³¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³²Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³³Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada
Background/Purpose: Shared decision making (SDM) improves decisional outcomes and patient-physician communication and holds great potential for improving the management of various rheumatology conditions. However, the…
Abstract Number: 2871 • 2018 ACR/ARHP Annual Meeting
Comprehensive Provider Judgement Is a Significant Determinant of Major Therapeutic Change in Patients with Moderate to Severe Rheumatoid Arthritis
Jacob R. Stever¹, Brian C. Sauer¹ and Grant W. Cannon², ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: We have previously reported an evaluation of 941 US Veterans in the Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry that 559 (59%)…

1
2
3
…
12
Next Page »